Revive Therapeutics Ltd. (RVVTF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $9.15M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRevive Therapeutics Ltd. (RVVTF) trades at $0.021. Revive Therapeutics Ltd. is a pharmaceutical company focused on developing therapeutics for rare disorders and infectious diseases. Market cap: $9.15M, Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for RVVTF: RVVTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Revive Therapeutics Ltd. (RVVTF) Healthcare & Pipeline Overview
Revive Therapeutics Ltd. is a life sciences company focused on developing cannabinoid and psilocybin-based pharmaceuticals for rare inflammatory diseases and infectious diseases like COVID-19. Their lead drug candidate, Bucillamine, is in Phase 3 clinical trials, positioning the company within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for RVVTF?
Revive Therapeutics presents a high-risk, high-reward investment profile typical of early-stage pharmaceutical companies. The primary value driver is the successful completion of Phase 3 clinical trials for Bucillamine, targeting infectious diseases. Positive trial results could lead to regulatory approval and subsequent revenue generation. The company's research into psilocybin-based therapies for mental health disorders and substance abuse represents a longer-term growth opportunity. However, the company's small market capitalization of $9.15M and negative P/E ratio of -2.44 indicate significant financial risks. Investors should carefully consider the inherent uncertainties associated with drug development and regulatory approval processes.
Based on FMP financials and quantitative analysis
RVVTF Key Highlights
Bucillamine is currently in Phase 3 clinical trials for the treatment of infectious diseases, including COVID-19.
- The company has a cannabinoid pharmaceutical portfolio focused on rare inflammatory diseases.
- Revive Therapeutics has research collaboration agreements with multiple universities and PharmaTher Inc. to expand its drug development pipeline.
- The company is developing Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder.
- The company's market capitalization is $9.15M.
Who Are RVVTF's Competitors?
RVVTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CPIVF Captiva Verde Wellness Corp. | $0.06 | 0.00% | $19.2M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RVVTF's Key Strengths?
Promising drug pipeline with Bucillamine in Phase 3 trials.
- Focus on unmet medical needs in rare disorders and infectious diseases.
- Strategic research collaborations with universities and PharmaTher Inc.
- Development of both cannabinoid and psilocybin-based therapeutics.
What Are RVVTF's Weaknesses?
Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Early-stage development of psilocybin-based therapies.
- Small number of employees.
What Could Drive RVVTF Stock Higher?
Completion of Phase 3 clinical trials for Bucillamine in treating infectious diseases.
- Publication of clinical trial results for Psilocybin in treating methamphetamine use disorder.
- Advancement of research collaborations with PharmaTher Inc. and other institutions.
- Development of cannabidiol-based therapies for autoimmune hepatitis.
- Exploration of new therapeutic applications for Bucillamine and Psilocybin.
What Are the Key Risks for RVVTF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for Bucillamine or other drug candidates.
- Unfavorable clinical trial results.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support research and development.
- Changes in government regulations regarding cannabinoid and psilocybin-based therapies.
What Are the Growth Opportunities for RVVTF?
- Expansion of Bucillamine's Application: Successful completion of Phase 3 trials for Bucillamine could lead to its approval for treating COVID-19 and other infectious diseases. The global market for COVID-19 therapeutics remains substantial, even as the pandemic evolves. Further research into Bucillamine's efficacy against various viral strains could extend its market reach and provide a significant revenue stream for Revive Therapeutics.
- Psilocybin-Based Therapies for Mental Health: The growing acceptance of psilocybin as a potential treatment for mental health disorders presents a significant growth opportunity. Revive Therapeutics' research into Psilocin for depression, anxiety, and other conditions positions it to capitalize on this emerging market. Positive results from Phase 1 clinical trials could attract further investment and partnerships.
- Cannabidiol for Autoimmune Hepatitis: The development of cannabidiol-based therapies for autoimmune hepatitis could address a significant unmet medical need. The market for autoimmune disease treatments is substantial and growing. Successful preclinical and clinical studies could lead to a valuable new product for Revive Therapeutics.
- Strategic Partnerships and Collaborations: Revive Therapeutics' existing research collaboration agreements with PharmaTher Inc., North Carolina State University, and other institutions provide access to cutting-edge research and development capabilities. Expanding these partnerships and forging new collaborations could accelerate the development of novel therapies and broaden the company's pipeline.
- Geographic Expansion: Currently headquartered in Canada, Revive Therapeutics has the opportunity to expand its operations into new geographic markets, particularly the United States and Europe. Establishing a presence in these regions could provide access to larger patient populations and increase the company's visibility among investors and potential partners.
What Are RVVTF's Competitive Advantages?
- Proprietary drug formulations and intellectual property.
- Research collaborations with leading universities and research institutions.
- Focus on niche markets with unmet medical needs.
- Advanced stage clinical trials for lead drug candidate, Bucillamine.
What Does RVVTF Do?
Revive Therapeutics Ltd., incorporated in 2012 and headquartered in Toronto, Canada, is a life sciences company dedicated to the research and development of novel therapeutics for rare disorders and infectious diseases. The company's primary focus is on developing treatments utilizing cannabinoid and psilocybin-based pharmaceuticals. Revive's pipeline includes Bucillamine, a drug in Phase 3 clinical trials for infectious diseases, including influenza and COVID-19. Additionally, the company is developing Psilocybin, currently in Phase 1 clinical study, for treating methamphetamine use disorder. Further research is being conducted on Psilocin for mental health conditions such as depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. The company is also exploring cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics collaborates with PharmaTher Inc., North Carolina State University, University of California, San Francisco, and University of Health Sciences Antigua to advance its research and development efforts. These collaborations focus on areas such as psilocybin development for cancer treatment, biosynthetic psilocybin production, Bucillamine's potential for treating severe COVID-19, and clinical research of psychedelics.
What Products and Services Does RVVTF Offer?
- Researches and develops therapeutics for rare disorders.
- Focuses on treatments for infectious diseases.
- Offers a cannabinoid pharmaceutical portfolio.
- Develops Bucillamine for infectious diseases, including COVID-19.
- Develops Psilocybin for treating methamphetamine use disorder.
- Researches Psilocin for mental health conditions.
- Explores cannabidiol for autoimmune hepatitis and organ transplantation injury.
How Does RVVTF Make Money?
- Develops pharmaceutical products through in-house research and development.
- Collaborates with universities and other research institutions to advance drug development.
- Seeks regulatory approval for its drug candidates.
- Plans to commercialize approved drugs through partnerships or direct sales.
What Industry Does RVVTF Operate In?
Revive Therapeutics operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory requirements. The industry is driven by the constant need for new and improved treatments for various diseases. Companies like Revive Therapeutics focus on niche markets, such as rare disorders and infectious diseases, to differentiate themselves. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. The development of novel therapies, particularly in areas like mental health and substance abuse, represents a significant growth opportunity within the industry.
Who Are RVVTF's Key Customers?
- Patients suffering from rare disorders.
- Patients with infectious diseases, including COVID-19.
- Individuals with methamphetamine use disorder.
- Patients with mental health conditions such as depression and anxiety.
- Individuals with autoimmune hepatitis.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Revive Therapeutics Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Michael Frank. RVVTF has traded publicly since 2015.
How Revive Therapeutics Ltd. Is Valued
Revive Therapeutics Ltd. carries a market capitalization of $9.15M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Revive Therapeutics Ltd. stands at 288.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -97.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Revive Therapeutics Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
RVVTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Promising drug pipeline with Bucillamine in Phase 3 trials.
- Focus on unmet medical needs in rare disorders and infectious diseases.
- Strategic research collaborations with universities and PharmaTher Inc.
- Development of both cannabinoid and psilocybin-based therapeutics.
Bear Case
- Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Early-stage development of psilocybin-based therapies.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RVVTF Latest News
-
Revive Therapeutics Announces Proposed Shares for Debt Settlement
accessnewswire.com · Aug 19, 2026
-
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
accessnewswire.com · Aug 19, 2026
-
Revive Therapeutics Reports Grant of Options
accessnewswire.com · Aug 14, 2026
-
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
accessnewswire.com · Aug 12, 2026
RVVTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RVVTF.
Price Targets
Wall Street price target analysis for RVVTF.
RVVTF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RVVTF; grades run from A+ (80-100) to F (below 30).
Latest News
Revive Therapeutics Announces Proposed Shares for Debt Settlement
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
Revive Therapeutics Reports Grant of Options
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Leadership: Michael Frank
CEO
Michael Frank serves as the CEO of Revive Therapeutics Ltd. His background includes experience in managing and leading small teams within the life sciences sector. He is responsible for overseeing the company's research and development efforts, strategic partnerships, and overall corporate strategy. His leadership is focused on advancing the company's drug pipeline and securing regulatory approvals.
Track Record: Under Michael Frank's leadership, Revive Therapeutics has advanced Bucillamine to Phase 3 clinical trials for infectious diseases. He has also overseen the expansion of the company's research into psilocybin-based therapies and the establishment of strategic collaborations with universities and PharmaTher Inc. His focus has been on driving the company's drug development programs forward.
RVVTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Revive Therapeutics may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower liquidity and higher price volatility.
- Potential for pump-and-dump schemes and other fraudulent activities.
- Greater risk of delisting or trading suspensions.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's capitalization structure and potential dilution.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Phase 3 clinical trials for Bucillamine.
- Research collaborations with reputable universities.
- Focus on developing therapeutics for unmet medical needs.
- Company incorporated in 2012.
Common Questions About RVVTF (Healthcare)
Is RVVTF a good stock to buy?
Stock Expert AI does not rate RVVTF buy, sell or hold. Revive Therapeutics Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RVVTF stock price today?
The last price recorded on this page for Revive Therapeutics Ltd. (RVVTF) is $0.021, as of the Oct 2, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Revive Therapeutics Ltd. do?
Revive Therapeutics Ltd. is a life sciences company focused on the research, development, and commercialization of novel therapeutics for rare disorders and infectious diseases.
What are the key factors to evaluate for RVVTF?
Evaluate RVVTF on fundamentals, analyst consensus, and risk factors. Bucillamine is currently in Phase 3 clinical trials for the treatment of infectious diseases, including COVID-19. Not financial advice.
How frequently does RVVTF data refresh on this page?
RVVTF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RVVTF's recent stock price performance?
Revive Therapeutics Ltd. (RVVTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising drug pipeline with Bucillamine in Phase 3 trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RVVTF overvalued or undervalued right now?
Revive Therapeutics Ltd. (RVVTF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RVVTF before investing?
Before investing in Revive Therapeutics Ltd. (RVVTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.